[HTML][HTML] Критический анализ концепции «цитокиновой бури» у пациентов с новой коронавирусной инфекцией COVID-19. Обзор литературы

СС Бобкова, АА Жуков, ДН Проценко… - … терапии имени АИ …, 2021 - cyberleninka.ru
Актуальность. Новая коронавирусная инфекция, вызванная вирусом SARS-CoV-2,
характеризуется системной гипервоспалительной реакцией с выраженным …

[HTML][HTML] Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of paxlovid against LUAD/COVID-19

W Zhang, Z Yang, F Zhou, Y Wei, X Ma - Frontiers in Endocrinology, 2022 - frontiersin.org
Background Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has caused a pandemic in many countries around …

[HTML][HTML] Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients

E Karatas, L Aksoy, E Ozaslan - Infection & Chemotherapy, 2021 - ncbi.nlm.nih.gov
Materials and Methods We examined patients with a clinical, laboratory, and radiological
diagnosis of severe coronavirus disease 2019 (COVID-19) pneumonia. We investigated the …

Anakinra—An Interleukin-1 Receptor Antagonist for COVID-19

T Nguyen, L Dima, KC Willett - American Journal of Therapeutics, 2023 - journals.lww.com
Background: Coronavirus disease (COVID-19) caused by SARS-CoV-2 virus caused a
global pandemic in 2019. There are limited pharmacologic options available. The Food and …

Age, gender, and 11 comorbidities as risk factors associated with COVID-19 mortality: A retrospective cohort including 1.8 million individuals

JC Cruz, CK Martins, A Katchborian Neto… - Journal of Toxicology …, 2023 - Taylor & Francis
The aim of this study was to investigate the risk factors age, gender, and 11 comorbidities for
mortality attributed to COVID− 19 among Brazilians. An observational, retrospective cohort …

[HTML][HTML] Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study

X Wang, Y Dian, Q Zhou, G Deng, R Wei… - Frontiers in …, 2023 - frontiersin.org
Background Current guidelines prioritize the use of Azvudine in Coronavirus Disease 2019
(COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients …

[HTML][HTML] COVID-19 outcomes and vaccination in patients with spondyloarthritis

A Deodhar, S Bhana, K Winthrop… - Rheumatology and therapy, 2022 - Springer
The rapid transmission of the highly infectious severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), led to …

Therapeutic and anti-inflammatory effects of baricitinib on mortality, ICU transfer, clinical improvement, and CRS-related laboratory parameters of hospitalized patients …

S Tahsini Tekantapeh, M Ghojazadeh… - Expert Review of …, 2022 - Taylor & Francis
Background Due to the high incidence and mortality of the worldwide COVID-19 pandemic,
beneficial effects of effective antiviral and anti-inflammatory drugs used in other diseases …

[HTML][HTML] Increased Pro Th1 And Th17 Transcriptional Activity In Patients With Severe COVID-19

M Jovanovic, S Sekulic, M Jocic… - … Journal of Medical …, 2023 - ncbi.nlm.nih.gov
Background: COVID-19 is known to disrupt immune response and induce
hyperinflammation that could potentially induce fatal outcome of the disease. Until now, it is …

[PDF][PDF] High-CBD cannabis extracts inhibit the expression of proinflammatory factors via miRNA-mediated silencing in human small intestinal epithelial cells

B Wang, D Li, A Fiselier, I Kovalchuk, O Kovalchuk - Heliyon, 2023 - cell.com
The incidence of chronic inflammatory disorders and autoimmune diseases is rapidly
growing. To date, the COVID-19 pandemic caused by SARS-CoV-2 has killed over …